论文部分内容阅读
目的 探讨适合中国人的他克莫司 (FK50 6)剂量。方法 对 8例使用高剂量FK50 6(0 .2mg·kg- 1 ·d- 1 )方案肾移植受者 (A组 )及 34例使用低剂量FK50 6(0 .1mg·kg- 1 ·d- 1 )受者 (B组 )术后早期血肌酐、排斥反应发生率及免疫抑制剂的不良反应进行比较。结果 A、B两组术后 2个月血肌酐水平的差异无显著性 (P >0 .0 5) ;A组半年内未见急性排斥反应发生 ;B组有 1例因血中FK50 6的浓度偏低而发生急性排斥反应 ,2例肾组织活检提示肾小管炎 ;两个组在随访期内均未见严重感染发生 ;药物的不良反应B组较少、较轻。结论 应用低剂量FK50 6组成的免疫抑制方案 ,在降低药物毒副作用的同时 ,并不影响其疗效
Objective To investigate the dosage of tacrolimus (FK50 6) suitable for Chinese. Methods A total of 8 renal transplant recipients (group A) with high dose of FK50 6 (0.2 mg · kg -1 · d -1) and 34 patients with low dose of FK50 6 (0.1 mg · kg -1 · d -1) 1) recipients (group B) postoperative serum creatinine, the incidence of rejection and adverse reactions of immunosuppressive agents were compared. Results There was no significant difference in serum creatinine level between the two groups at 2 months after operation (P> 0.05). No acute rejection occurred within 6 months in group A, 1 case in group B due to FK506 Acute rejection occurred with low concentration, and renal biopsy in 2 cases showed tubulitis. No serious infection occurred in both groups during the follow-up period. Adverse reactions of drugs were less in group B and lighter. Conclusions The immunosuppressive regimen with low dose of FK50 6 has no effect on reducing drug toxicity and side effects